Guidelines & Consensus
Real-World Achievement of Guideline-Concordant Treatment and Survival in Osteosarcoma: A Nationwide Registry Study
Fujiwara et alCancer Science
In a nationwide registry analysis from the Japanese Bone and Soft Tissue Tumor Registry evaluating 1,149 patients treated between 2011 and 2020, 84% (n = 969) achieved guideline-concordant treatment for osteosarcoma. Concordance rates varied by clinical stage, reaching 85% in localized low-grade disease, 83% in localized high-grade disease, and 90% in metastatic osteosarcoma. There were no significant geographic disparities in achievement rates across Japan, reflecting a uniform standard of care nationwide.\n\nGuideline-concordant care conferred substantial survival benefits across all stages. In localized low-grade osteosarcoma, concordance was associated with superior 5-year disease-specific survival (DSS) of 97% compared to 68% for non-concordant care (p = 0.007), with trunk tumor location identified as a factor associated with non-concordance. In localized high-grade osteosarcoma, concordant care achieved a 5-year DSS of 78% versus 50% (p < 0.001). While concordant care was linked to improved 5-year DSS in patients aged 40 years or younger (82% vs. 50%, p < 0.001) and in those over 40 years (61% vs. 50%, p = 0.030), a sensitivity analysis limited to localized high-grade extremity tumors found this association remained statistically significant only in patients aged 40 years and younger. Trunk location and age greater than 40 years were both associated with non-concordance in localized high-grade disease.\n\nFor patients presenting with metastatic osteosarcoma, guideline-concordant treatment demonstrated a significant survival advantage, improving 2-year DSS from 16% with non-concordant treatment to 54% (p < 0.001). Overall, treatment feasibility substantially impacted therapy completion and survival, particularly in older individuals. These real-world findings reinforce the critical role of wide or radical surgical resection and perioperative chemotherapy whenever clinically feasible.
Key Takeaways
- Guideline-concordant treatment was associated with significantly superior 5-year disease-specific survival compared with non-concordant care in localized low-grade (97% vs. 68%, p = 0.007) and localized high-grade osteosarcoma (78% vs. 50%, p < 0.001).
- In metastatic osteosarcoma, receipt of guideline-concordant therapy yielded a markedly higher 2-year disease-specific survival compared with non-concordant treatment (54% vs. 16%, p < 0.001).
- Across 1,149 registry patients, overall guideline concordance reached 84%, with non-concordance significantly driven by trunk tumor location and age over 40 years.
Read the original sourceCancer Science
